Skip to main content
Top
Published in: neurogenetics 2/2013

01-05-2013 | Original Article

Natural history of neurofibromatosis type 2 with onset before the age of 1 year

Authors: Martino Ruggieri, Anna Lia Gabriele, Agata Polizzi, Vincenzo Salpietro, Francesco Nicita, Piero Pavone, Nunzio Platania, Pietro Milone, Angela Distefano, Giuseppe Privitera, Giuseppe Belfiore, Francesca Granata, Rosario Caltabiano, Vincenzo Albanese, Lorenzo Pavone, Aldo Quattrone

Published in: Neurogenetics | Issue 2/2013

Login to get access

Abstract

Neurofibromatosis type 2 (NF2) with onset before the first year of life has been anecdotally reported in the literature. We (a) prospectively (years 1997–2012) followed up three unrelated NF2 children, all harbouring NF2 gene mutations whose onset of disease was before age 1 year, and (b) systematically reviewed published reports on NF2 in the youngest age group (i.e. onset <1 year). The present three children had (1) small (<1 cm), bilateral vestibular schwannomas (VSs) detected (as an incidental finding) at magnetic resonance imaging (MRI) by the age of 4 to 5 months that were asymptomatic for 10 to 14 years, with sudden and rapid (<12 months) progression in two cases at the age of 11 and 15 years, respectively; (2) development of large numbers of skin NF2 plaques mainly in atypical locations (i.e. face, hands, legs and knees), which reverted to normal skin appearance at the time of VSs progression; (3) lens opacities (n = 1) and NF2 retinal changes (n = 2) detected as early as age of 3-4 months; (4) diffuse (asymptomatic) high signal lesions at brain MRI in the periventricular regions (alike cortical dysplasia); and (5) unaffected first-degree relatives who did not harbour NF2 gene abnormalities. This represents the youngest NF2 group with the longest prospective follow-up so far reported. NF2 may present as a congenital form with bilateral VSs presenting as early as the first months of life and with natural history different to that which occurs in classical NF2.
Literature
1.
go back to reference Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, Evans DG (2011) Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 13:576–81 Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, Evans DG (2011) Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 13:576–81
2.
go back to reference Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L (2005) Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 36:21–34PubMedCrossRef Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L (2005) Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 36:21–34PubMedCrossRef
3.
go back to reference Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618PubMed Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618PubMed
4.
go back to reference Mautner VE, Tatagiba M, Guthoff R, Samili M, Pulst SM (1993) Neurofibromatosis type 2 in the pediatric age. Neurosurgery 33:92–96PubMedCrossRef Mautner VE, Tatagiba M, Guthoff R, Samili M, Pulst SM (1993) Neurofibromatosis type 2 in the pediatric age. Neurosurgery 33:92–96PubMedCrossRef
5.
go back to reference MacCollin M, Mautner VE (1998) The diagnosis and management of neurofibromatosis type 2 in childhood. Semin Pediatr Neurol 5:243–252PubMedCrossRef MacCollin M, Mautner VE (1998) The diagnosis and management of neurofibromatosis type 2 in childhood. Semin Pediatr Neurol 5:243–252PubMedCrossRef
6.
go back to reference Evans DG, Birch JM, Ramsden RT (1999) Pediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496–499PubMedCrossRef Evans DG, Birch JM, Ramsden RT (1999) Pediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496–499PubMedCrossRef
7.
go back to reference Ruggieri M, Huson SM (1999) Clinical presentations of neurofibromatosis type 2 in childhood. Eur J Pediatr Neurol 3:66 Ruggieri M, Huson SM (1999) Clinical presentations of neurofibromatosis type 2 in childhood. Eur J Pediatr Neurol 3:66
8.
go back to reference Nunes F, MacCollin M (2002) Neurofibromatosis type 2 in the pediatric population. J Child Neurol 18:718–724CrossRef Nunes F, MacCollin M (2002) Neurofibromatosis type 2 in the pediatric population. J Child Neurol 18:718–724CrossRef
9.
go back to reference Rushing EJ, Olsen C, Mena H, Rueda ME, Lee YS, Keating RF, Packer RJ, Santi M (2005) Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg 103(Suppl):489–495PubMed Rushing EJ, Olsen C, Mena H, Rueda ME, Lee YS, Keating RF, Packer RJ, Santi M (2005) Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg 103(Suppl):489–495PubMed
10.
go back to reference Bosch MM, Boltshauser E, Harpes P, Landau K (2006) Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol 141:1068–1077PubMedCrossRef Bosch MM, Boltshauser E, Harpes P, Landau K (2006) Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol 141:1068–1077PubMedCrossRef
11.
go back to reference Pascual-Castroviejo I, Pascual-Pascual SI, Viaño J (2009) Neurofibromatosis type 2 (NF2). Study of 7 patients. Neurologia 24:457–461PubMed Pascual-Castroviejo I, Pascual-Pascual SI, Viaño J (2009) Neurofibromatosis type 2 (NF2). Study of 7 patients. Neurologia 24:457–461PubMed
12.
go back to reference Ruggieri M, Huson S (2001) The clinical and diagnostic implications of mosaicism in the neurofibromatosis. Neurology 56:1433–1443PubMedCrossRef Ruggieri M, Huson S (2001) The clinical and diagnostic implications of mosaicism in the neurofibromatosis. Neurology 56:1433–1443PubMedCrossRef
13.
go back to reference Huson SM, Hughes RAC (1994) The neurofibromatoses. A pathogenic and clinical overview. Churchill Livingstone, London Huson SM, Hughes RAC (1994) The neurofibromatoses. A pathogenic and clinical overview. Churchill Livingstone, London
14.
go back to reference Ruggieri M, Pacual-Castroviejo I, Di Rocco C (2008) Neurocutaneous disorders. Phakomatoses and hamartoneoplastic syndromes. Springer, New YorkCrossRef Ruggieri M, Pacual-Castroviejo I, Di Rocco C (2008) Neurocutaneous disorders. Phakomatoses and hamartoneoplastic syndromes. Springer, New YorkCrossRef
15.
go back to reference Pavone P, Spalice A, Polizzi A, Parisi P, Ruggieri M (2012) Ohtahara syndrome with emphasis on recent genetic discovery. Brain Dev 34:459–468 Pavone P, Spalice A, Polizzi A, Parisi P, Ruggieri M (2012) Ohtahara syndrome with emphasis on recent genetic discovery. Brain Dev 34:459–468
16.
go back to reference Ruggieri M, Iannetti P, Clementi M, Polizzi A, Incorpora G, Spalice A, Pavone P, Praticò AD, Elia M, Gabriele AL, Tenconi R, Pavone L (2009)Neurofibromatosis type 1 and infantile spasms. Childs Nerv Syst 25:211–6 Ruggieri M, Iannetti P, Clementi M, Polizzi A, Incorpora G, Spalice A, Pavone P, Praticò AD, Elia M, Gabriele AL, Tenconi R, Pavone L (2009)Neurofibromatosis type 1 and infantile spasms. Childs Nerv Syst 25:211–6
17.
go back to reference Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367PubMedCrossRef Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367PubMedCrossRef
18.
go back to reference Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14–18PubMedCrossRef Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14–18PubMedCrossRef
19.
go back to reference Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–5PubMedCrossRef Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–5PubMedCrossRef
Metadata
Title
Natural history of neurofibromatosis type 2 with onset before the age of 1 year
Authors
Martino Ruggieri
Anna Lia Gabriele
Agata Polizzi
Vincenzo Salpietro
Francesco Nicita
Piero Pavone
Nunzio Platania
Pietro Milone
Angela Distefano
Giuseppe Privitera
Giuseppe Belfiore
Francesca Granata
Rosario Caltabiano
Vincenzo Albanese
Lorenzo Pavone
Aldo Quattrone
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Neurogenetics / Issue 2/2013
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI
https://doi.org/10.1007/s10048-013-0354-0

Other articles of this Issue 2/2013

neurogenetics 2/2013 Go to the issue